Erythropoietic Protoporphyria Market Forecast
Erythropoietic protoporphyria is a rare inherited metabolic disorder that is a result of a deficiency or inappropriate functioning of the enzyme ferrochelatase (FECH) owing to mutations in the FECH gene that leads to excessive amounts of protoporphyrin accumulate in the bone marrow, blood plasma, and red blood cells.
At present, the Erythropoietic Protoporphyria market lacks curative treatment options. Erythropoietic protoporphyria poses a huge burden to healthcare. To fulfill the unmet need, pharmaceutical companies such as Mitsubishi Tanabe Pharma Corporation (MTPC) and others are proactively working to launch their novel therapeutic candidates in the Erythropoietic protoporphyria market in the upcoming years.
For more details, visit: Erythropoietic Protoporphyria Market Forecast